https://wikimd.com/index.php?action=history&feed=atom&title=HGSNATHGSNAT - Revision history2026-04-20T19:25:13ZRevision history for this page on the wikiMediaWiki 1.44.2https://wikimd.com/index.php?title=HGSNAT&diff=6023381&oldid=prevPrab: CSV import2024-12-02T03:56:03Z<p>CSV import</p>
<p><b>New page</b></p><div>{{DISPLAYTITLE:HGSNAT}}<br />
<br />
== Overview ==<br />
'''HGSNAT''' (Heparan-alpha-glucosaminide N-acetyltransferase) is an enzyme encoded by the '''HGSNAT''' gene in humans. This enzyme is crucial in the degradation of [[heparan sulfate]], a complex carbohydrate that is part of the [[glycosaminoglycan]] family. The proper function of HGSNAT is essential for the lysosomal breakdown of heparan sulfate, and mutations in the HGSNAT gene can lead to [[mucopolysaccharidosis type IIIC]] (MPS IIIC), also known as [[Sanfilippo syndrome type C]].<br />
<br />
== Function ==<br />
HGSNAT is involved in the lysosomal degradation pathway of heparan sulfate. It catalyzes the acetylation of the terminal glucosamine residue in heparan sulfate, a necessary step for its subsequent breakdown. This process is vital for cellular homeostasis and the recycling of cellular components.<br />
<br />
== Genetic Information ==<br />
The '''HGSNAT''' gene is located on chromosome 8 (8p11.1) and consists of multiple exons. Mutations in this gene can lead to a deficiency in the HGSNAT enzyme, resulting in the accumulation of heparan sulfate in lysosomes, which is characteristic of MPS IIIC.<br />
<br />
== Clinical Significance ==<br />
Mutations in the HGSNAT gene are associated with [[Sanfilippo syndrome type C]], a rare autosomal recessive lysosomal storage disorder. This condition is characterized by progressive neurodegeneration, developmental delay, behavioral problems, and a shortened lifespan. Diagnosis is typically confirmed through genetic testing and enzyme assays.<br />
<br />
== Research and Therapeutic Approaches ==<br />
Research into HGSNAT and its associated disorders is ongoing, with efforts focused on gene therapy, enzyme replacement therapy, and substrate reduction therapy. These approaches aim to correct the underlying enzyme deficiency or reduce the accumulation of heparan sulfate.<br />
<br />
== Also see ==<br />
* [[Mucopolysaccharidosis]]<br />
* [[Lysosomal storage disorder]]<br />
* [[Heparan sulfate]]<br />
* [[Sanfilippo syndrome]]<br />
<br />
== References ==<br />
<references/><br />
<br />
{{Lysosomal storage disorders}}<br />
{{Genetic disorders}}<br />
<br />
[[Category:Enzymes]]<br />
[[Category:Genetic disorders]]<br />
[[Category:Lysosomal storage disorders]]</div>Prab